



# Bal Pharma Limited

21.12.2023

To,  
The Manager-Listing  
BSE Limited  
Mumbai.

To  
The Manager-Listing  
National Stock Exchange of India Ltd  
Mumbai.

Dear Sir,

**Sub: Proceedings of NCLT convened meetings of Shareholders, Secured and Unsecured Creditors of the Company held on 21.12.2023.**

**Ref : Scrip code 524824 for BSE and BALPHARMA for NSE.**

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting to the exchange the business transacted at the NCLT convened meetings of Shareholders , Secured and Unsecured creditors of the Company , conducted through audio visual means on 21.12.2023.

Mr.Theerthesh appointed by honourable NCLT as Chairman of the meeting, chaired the proceedings of the meeting with requisite quorum and transacted the following business.

## Special Business:

1. Approved the Scheme of Merger by Amalgamation of Golden Drugs Private Limited (Transferer Company ) with its holding Company i.e Bal Pharma Limited (Transferee Company) and their respective shareholders."

Chairman provided a brief overview on the scheme of arrangement . Queries from the shareholders received through e-mail will also be addressed suitably by the Chairman.

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. :080-41570811 / 13 / 19 Fax : 41570820





# Bal Pharma Limited

Page-2

Mr. Vishnu Kumar PA, Practising Company Secretary was appointed as the scrutinizer for the e-voting by Hon'ble NCLT and the results of e-voting will be announced after receipt of Scrutinizer's Report.

The e-voting results will be submitted to the exchanges as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and also uploaded on our website.

The NCLT convened meetings has commenced at 11.00 AM as scheduled and concluded at 02:40 PM on 21.12.2023.

Please take this intimation on record.

Thanking you

For Bal Pharma Limited

Shailesh Siroya  
Managing Director.



SHAILESH  
SIROYA

Digitally signed by SHAILESH SIROYA  
DN: cn=N, postalCode=560020, st=KARNATAKA,  
street=BANGALORE, l=BANGALORE, o=Personal,  
serialNumber=0330e066c935c3297209558c1bf  
3254e93784f1fce82b06c27b061000bc5,  
pseudonym=07ef3b75f99346ab9ed3b1b569116  
526,  
2.5.4.20=09c84def7c50eedf25417ba5a55f5bbe  
c797e111b971e0e47d44402ee6eab0,  
email=MDSECT@BALPHARMA.COM,  
cn=SHAILESH SIROYA  
Date: 2023.12.21 15:10:15 +05'30'

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052, India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. :080-41570811 / 13 / 19 Fax : 41570820